Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Depreciation & Amortization (CF): 2014-2025

Historic Depreciation & Amortization (CF) for ImmunityBio (IBRX) over the last 12 years, with Sep 2025 value amounting to $4.0 million.

  • ImmunityBio's Depreciation & Amortization (CF) fell 11.31% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.8 million, marking a year-over-year decrease of 12.14%. This contributed to the annual value of $17.6 million for FY2024, which is 5.18% down from last year.
  • As of Q3 2025, ImmunityBio's Depreciation & Amortization (CF) stood at $4.0 million, which was up 1.83% from $3.9 million recorded in Q2 2025.
  • ImmunityBio's Depreciation & Amortization (CF)'s 5-year high stood at $5.2 million during Q4 2022, with a 5-year trough of $3.0 million in Q1 2021.
  • Over the past 3 years, ImmunityBio's median Depreciation & Amortization (CF) value was $4.5 million (recorded in 2024), while the average stood at $4.3 million.
  • Per our database at Business Quant, ImmunityBio's Depreciation & Amortization (CF) surged by 61.50% in 2021 and then dropped by 15.94% in 2025.
  • Over the past 5 years, ImmunityBio's Depreciation & Amortization (CF) (Quarterly) stood at $3.6 million in 2021, then surged by 45.37% to $5.2 million in 2022, then declined by 12.67% to $4.6 million in 2023, then fell by 9.33% to $4.1 million in 2024, then dropped by 11.31% to $4.0 million in 2025.
  • Its Depreciation & Amortization (CF) was $4.0 million in Q3 2025, compared to $3.9 million in Q2 2025 and $3.8 million in Q1 2025.